Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors

study evaluates EB-NK-301, an investigational off-the-shelf allogeneic CAR-NK cell product targeting TROP2, in adults with advanced or metastatic solid tumors that express TROP2 and have progressed after standard therapy. The primary goals are to assess safety and tolerability, identify dose-limiting toxicities (DLTs), and determine a recommended Phase 2 dose (RP2D). Secondary goals include preliminary anti-tumor activity, persistence of infused CAR-NK cells, and exploratory immune biomarkers.

NCT Number	NCT07589530
Lead Sponsor	Beijing Biotech
Conditions	Advanced Solid Tumors, Metastatic Solid Tumors, TROP2-Expressing Solid Tumors
Enrollment	60 participants
Start Date	2026-03-02
Primary Completion	2027-02-14 (estimated)
Study Completion	2028-03-17 (estimated)
Updated on ClinicalTrials.gov	2026-05-15